Cite
HARVARD Citation
Smit, E. et al. (2016). A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS). Lung cancer. pp. 94-101. [Online].